FindTrial
Sign In

A clinical trial to study the effects of Rifaximin therapy on children with small intestinal bacterial overgrowth.

To study the effect of Rifaximin therapy on children with small intestinal bacterial overgrowth. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099885
Enrollment
60
Registered
2025-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R143- Flatulence

Interventions

Intervention1: Rifaximin @ 7.5mg/kg x 10 days: To measure the change in H2 concentration by lactulose breath test after 2 weeks of completion of Rifaximin therapy in children with small intestinal bac

Sponsors

Falak Zaidi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children having Small Intestinal Bcaterial Overgrowth confirmed by abnormal lactulose breath test.

Exclusion criteria

Exclusion criteria: Medical conditions: History of any chronic disease. Use of antibiotics or probiotics within 2 months prior to enrollment. History of allergy to Rifaximin or Rifampin.

Design outcomes

Primary

MeasureTime frame
We will be able to find out the effect of Rifaximin therapy on children with small intestinal bacterial overgrowth. We will be able to find out the overall improvement in symptoms after treatment according to NRS questionnaireTimepoint: 24 days—

Secondary

MeasureTime frame
To study the clinical profile of children with Small Intestinal Bacterial Overgrowth.Timepoint: 24 days—

Countries

India

Contacts

Public ContactFalak Zaidi

Era medical college

786falak.zaidi@gmail.com8076205624

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026